Haag-Streit Names Thomas Lenzen as CEO

Haag-Streit has announced the appointment of Thomas Lenzen as the new Chief Executive Officer (CEO) of the Haag-Streit Group, effective September 1, 2025. He will succeed Thomas Bernhard, who has served as CEO since 2021.

Professional Background and Industry Experience

Thomas Lenzen brings over 20 years of international leadership experience in the medical technology sector, with a background in ophthalmology and business operations.

He previously led the Surgical Business Unit for the DACH region at Bausch + Lomb and later served as General Manager for the same region. Most recently, he was Vice President International at Haemonetics, where he oversaw global operations for the company’s plasma and blood center business unit.

In a statement, Lenzen shared his perspective on the new role:

“Haag-Streit has a remarkable history of shaping ophthalmology through pioneering solutions and a strong commitment to precision and quality. I am honored to lead the company into its next phase of growth. Together with my new colleagues around the world, I look forward to building on the strength of the current portfolio and driving our strategy forward with energy, innovation, and passion.”

Reflections from Outgoing CEO Thomas Bernhard

Outgoing CEO Thomas Bernhard expressed appreciation for his time with the company and welcomed the leadership transition:

“It has been a privilege to serve Haag-Streit for more than a decade, and I am proud of what we have achieved together as “One Haag-Streit.” Our groundbreaking innovations, including the Eyestar 900, METIS 900, Elara 900, and Refractor 900, alongside the transformation of individual companies into a cohesive and strategically unified organization, have laid a powerful foundation for future growth. I warmly welcome Thomas Lenzen as my successor and wish him every success in this exciting role.”